The Cystic Fibrosis Foundation (CFF) recently approved support for a two-year research study by Joshua Chandler, PhD, a postdoctoral research fellow in the Emory Division of Pulmonary, Allergy, Critical Care and Sleep Medicine. The CFF will help support Dr. Chandler’s project, “Thiocyanate switching of oxidative mechanisms in cystic fibrosis,” from April 1, 2016 to March 31, 2018.
Dr. Chandler received a PhD in toxicology from the University of Colorado in 2014 and bachelor’s degrees in chemistry and biology from Drury University in 2009. His research experience includes work in redox biology, respiratory toxicology, immunology, infectious diseases, biopharmaceutical formulation, and adjuvant evaluation. He wrote his PhD thesis on the role of thiocyanate in infectious and inflammatory lung diseases such as cystic fibrosis (CF).
By working with Dean P. Jones, PhD (Division of Pulmonary, Allergy, Critical Care and Sleep Medicine), Dr. Chandler hopes to extend the results of his thesis research into the world of omics data, with a primary goal of identifying specific targets of inflammatory oxidants with demonstrably different effects on human cells. A major long-term goal of his research is to develop a means to fine-tune oxidant generation in human patients to improve health outcomes without disrupting beneficial immunologic processes.
Related Links
